Each year, thousands of lawsuits are filed in federal and state courts seeking recovery from manufacturers of pharmaceuticals and medical devices. These lawsuits include individual actions, actions consolidated into multidistrict litigation, and class actions. The litigation occasionally becomes life-threatening for the defendant corporations, and may breed a public relations nightmare, as occurred with Vioxx, breast implants, and fen-phen. Drug and Device Product Liability Litigation Strategy, by Mark Herrmann and David B. Alden, offers assistance to lawyers who practice in this high-stakes, high-profile, and rapidly-evolving area. The book's primary focus is to provide useful practice pointers and overall strategic guidance for attorneys in product liability litigation involving prescription drugs and medical devices. It will serve as an indispensable guide to handling such a case from pre-litigation through trial. The legal landscape in this important area is expected to shift as the Supreme Court's decisions in Riegel v. Medtronic, Inc. and Wyeth v. Levine are applied, and as the President and Congress address tort reform and other health care issues. Practitioners will need thoughtful, expert advice to navigate these changes.... to dismiss and for summary judgmenta), available at http://www.fjc.gov/public/ pdf.nsf/lookup/mdljudge.pdf/$file/mdljudge.pdf. ... only those that are a#39;coordinated or consolidateda#39;a) (quoting In re Am. Continental Corp./Lincoln Sav. aamp; Loan Sec. Litig., 102 F.3d ... Milberg Weiss Bershad Hynes aamp; Lerach, 523 U.S. 26 (1998)).
|Title||:||Drug and Device Product Liability Litigation Strategy|
|Author||:||Mark Herrmann, David B. Alden|
|Publisher||:||Oxford University Press - 2011-11-23|